Comparison of cannabis-based medicinal product formulations for fibromyalgia: a cohort study
Author(s)
Type
Journal Article
Abstract
This cohort study aims to assess the outcomes of fibromyalgia patients enrolled in the UK Medical Cannabis Registry prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). A cohort study of fibromyalgia patients treated with oils (Adven®, Curaleaf International, UK), dried flower (Adven®, Curaleaf International, UK) or both CBMPs was performed. Primary outcomes were changes from baseline at 1, 3, 6 and 12 months in validated patient-reported outcome measures. Secondary outcomes included descriptive analysis of adverse events. One hundred and forty-eight participants were treated with oils (n = 77; 52.03%), dried flower (n = 14; 9.46%) or both (n = 57; 38.51%). Improvements in the generalized anxiety disorder-7 questionnaire, single-item sleep quality scale, fibromyalgia symptom severity score and EQ-5D-5L Index values were observed at each follow up period compared to baseline (p < 0.050). Thirty-six (24.32%) patients experienced 648 adverse events. Improvements were observed across all primary outcomes with no differences observed across different formulations of CBMPs. Adverse events were reported by one-quarter of participants and were more likely to reported by cannabis naïve patients. This present work through focusing on a homogeneous group of CBMPs can help inform randomized controlled trials after observing signals of improvement associated with a specific cultivar of CBMPs.
Date Issued
2024-10-17
Date Acceptance
2024-10-03
Citation
Journal of Pain and Palliative Care Pharmacotherapy, 2024, 39 (1), pp.24-37
ISSN
0742-969X
Publisher
Taylor and Francis Group
Start Page
24
End Page
37
Journal / Book Title
Journal of Pain and Palliative Care Pharmacotherapy
Volume
39
Issue
1
Copyright Statement
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
Identifier
https://www.tandfonline.com/doi/full/10.1080/15360288.2024.2414073
Subjects
Anesthesiology
cannabidiol
chronic pain
Fibromyalgia
GENERALIZED ANXIETY DISORDER
INDEX
INSOMNIA
Life Sciences & Biomedicine
medical cannabis
OUTCOMES
Pharmacology & Pharmacy
Science & Technology
SENSITIVITY
SLEEP
tetrahydrocannabinol
VALIDATION
Publication Status
Published
Date Publish Online
2024-10-17